Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients

• Published in: Kidney international Vol. 67; no. 3; pp. 1171 - 1178
• Main Authors: Nakanishi, Shohei, Kazama, Junichiro James, Nii-Kono, Tomoko, Omori, Kentaro, Yamashita, Takeyoshi, Fukumoto, Seiji, Gejyo, Fumitake, Shigematsu, Takashi, Fukagawa, Masafumi
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.03.2005; Nature Publishing; Elsevier Limited
• Subjects: Adult; Aged; Biological and medical sciences; dialysis; Endocrinopathies; Female; FGF-23; Fibroblast Growth Factors - blood; Humans; hyperparathyroidism; Hyperparathyroidism, Secondary - blood; Hyperparathyroidism, Secondary - etiology; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Parathyroid Hormone - blood; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases); phosphate; PTH; Renal Dialysis - adverse effects; vitamin D; dialysis; phosphate; hyperparathyroidism; FGF-23; PTH; vitamin D; Endocrinopathy; Human; Phosphates; Fibroblast growth factor; Treatment resistance; Nephrology; Urology; Refractory; Parathormone; Vitamin D; Parathyroid hormone; Parathyroid diseases; Dialysis; Predictive factor; Serum factor; Hyperparathyroidism
• ISSN: 0085-2538; 1523-1755
• DOI: 10.1111/j.1523-1755.2005.00184.x

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Secondary hyperparathyroidism is a common complication among long-term dialysis patients. The method of predicting future parathyroid function has not yet been established. Fibroblast growth factor-23 (FGF-23) is a newly found humoral phosphaturic factor. One hundred and three nondiabetic dialysis patients whose plasma intact parathyroid hormone (PTH) levels were below 300 pg/mL were included in the study. Blood samples were stored at -80°C for 2 years. Meanwhile, each physician in charge decided upon the strategy of medical therapy for maintaining intact PTH levels between 150 and 300 pg/mL. Patients were judged 2 years after the sample collection with regard to whether the hyperparathyroidism responded to the medical therapy. The definition of refractory secondary hyperparathyroidism was either (1) retaining intact PTH levels greater than 300 pg/mL 2 years after sample collection, or (2) having received the parathyroid intervention therapy during the observation period. Serum FGF-23 levels were determined with a sandwich enzyme-linked immunosorbent assay system that detects biologically active human FGF-23. Seventeen patients with intact PTH levels greater than 300 pg/mL were judged as having secondary hyperparathyroidism refractory to medical therapy. A stepwise regression analysis revealed that only serum levels of FGF-23 were significantly related to the prognosis of parathyroid function. A receiver-operated characteristic analysis demonstrated that the area under the curves obtained from FGF-23 (7099.9) was significantly greater than that obtained from intact PTH (6306.4, P < .01) and Ca × Pi (5670.3, P <.0001). Although the plasma intact PTH levels at the beginning of the observation period were comparable to each other, the intact PTH levels at 2 years after the sample collection were significantly higher in the patients with FGF-23 ≥7500 ng/L than in those with FGF-23 <7500 ng/L (P < .0001). Serum FGF-23 level was found to be the most useful factor in predicting future development of refractory secondary hyperparathyroidism in long-term dialysis patients with mild secondary hyperparathyroidism. The measurement of serum FGF-23 levels is a promising laboratory examination that can be applied in the clinical practice of uremic secondary hyperparathyroidism.